Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Control Bionics Ltd. ( (AU:CBL) ) is now available.
Control Bionics has signed a two-year US distribution agreement with AAC specialist PRC-Saltillo for its NeuroNode technology, formalising a relationship that has already seen PRC staff trained, devices used in trials and demonstrations, and insurance funding secured for clients. The deal broadens access to NeuroNode’s sEMG-based access method as a complementary option within PRC’s communication portfolio, underpins Control Bionics’ strategy of scaling NeuroNode sales through key regional partners, and is expected to support a gradual but sustainable ramp-up of US revenues following its recent partnership with Tobii Dynavox.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics Limited is an Australia-based medical device company specialising in surface electromyography (EMG)–based assistive technologies that enable communication and computer control for people with severe physical and communication disabilities. Its core patented NeuroNode wearable device interprets minute neural signals to drive speech and digital interaction, integrating touch, eye-gaze and NeuroNode control, and the company is expanding its technology platform, including the miniaturised NeuroStrip, into broader markets such as health diagnostics, sports performance and rehabilitation across North America, Australia, Singapore and Japan.
Average Trading Volume: 1,136,265
Technical Sentiment Signal: Buy
Current Market Cap: A$28.43M
For detailed information about CBL stock, go to TipRanks’ Stock Analysis page.